The anti-urokinase-IgG-resistant plasminogen activator secreted by humanembryonic lung diploid fibroblasts, IMR-90 cells (ATCC, C.CL186) was purified to homogeneity from serum-free conditioned medium by a four-step procedure. The fibroblast plasminogen activator was identified as tissue plasminogen activator (t-PA) by the N-terminal sequence of the purified material and the complete amino acid sequence deduced from its complementary DNA(CDNA).The apparent molecular weight was in the range of 64,000 to 68,000 by SDS-PAGEand was in the range of 69,000 to 72,000 by gel filtration. The fibroblast t-PA showed a stricter substrate specificity than urokinase in enzymatic hydrolysis of various chromogenic substrates. Compared to urokinase, the fibrobrast t-PA was more stable by heating at 95°C for five min and was stable from pH 5 to 10. The fibrobrast t-PA had a higher affinity for fibrin than urokinase.
tumor cells in culture.1} PA has been classified into two types of PA, urokinase-like activator and tissue plasminogen activator (t-PA). Concerning PA produced by normal cells, Vetterlein et al.2'3) showed that normal diploid fibroblasts, IMR-90 cells, produced urokinase with MW55,000 and anti-urokinase-IgGresistant PA with MW73,000. Wilson et alf ound that normal tissue, 8-week embryonic fibroblasts, produced PAwith an approximate MW70,000, which was immunologically distinct from urokinase. They also found that cells derived from most normal adult tissue or from a 26-week-old embryo produced only urokinase type PA with MW60,000. t-PA produced by human melanoma cells in culture has been purified and characterized by Rijken In this study, we have purified the antiurokinase-IgG-resistant plasminogen activator from serum-free conditioned medium of IMR-90 cells and identified it as tissue plasminogen activator (t-PA) by the N-terminus sequencing of the purified material and the complete amino acid sequence by cloning its complementary DNA(CDNA). We have also characterized the fibroblast t-PA compared to urokinase.
Materials and Methods
Materials. The reference preparation of human urokinase was supplied by the National institute for Biological Standards and Control, London, U.K. Urokinase and thrombin were purchased from Mochida Pharmaceutical Co., Japan. Purified high and low molecular weight urokinase preparations were from Green proteose peptone. To avoid the cleavage of plasminogen activator (PA), aprotinin, an inhibitor of serine proteases such as plasmin, was added to the serum-free mediumto a concentration of 50KlU/ml. After incubation for 4 to 5 days, the serum-free conditioned medium was harvested and centrifuged or filtered to remove cell debris.
Purification of anti-urokinase-IgG-resistant plasminogen activatorfrom IMR-90 cells. The serum-free medium (6.5 1), which was used as a starting material for the purification, had a total activity of 7.93 x 105 IU. The whole procedure was done at 3^°C. The serum-free conditioned medium wasput directly on a Zn-chelate Sepharose 6B column (04 x 19cm) equilibrated with 0.02 m Tris-HCl buffer, pH 7.5, containing 1m NaCl and 0.01% Tween 80 at a flow rate of 200ml/hr.
After the column was washed with equilibration buffer until^4280nm was less than 0.01, protein was eluted with 0.05m imidazole in the equilibration buffer. Fractions of 6ml were collected at a flow rate of 120 ml/hr. To remove urokinase, the active fractions from the Zn-chelating Sepharose 6B were put on an anti-urokinase polyclonal IgG-CNBr Sepharose 6B column (02 x 16cm), which was prepared by coupling IgG Assay for activity of plasminogen activator. The fibrinolytic activity was measured on fibrin-agarose plates by the method of Hasegawa.6) The plasminogen activator activity was comparedwith a reference preparation of human urokinase. Anti-urokinase-IgG-resistant PAactivity in the cell culture broth was defined as the residual activity after quenching the PA activity by anti-urokinase polyclonal antibody.
Protein concentration. Protein concentration was measured by the method of Lowry et al.1) SDS-PAGE. SDS-PAGE was done by the method of Weber and Osborn8) using 7.5% gels. Gels were stained with Coomassie Brilliant Blue. Molecular weight was measured using a low molecular weight calibration kit (Pharmacia, Sweden).
Amino acid sequence. Carboxymethylated PA was prepared by the published method.9) The amino acids were sequenced using an automated gas-phase sequence analyzer (470A protein sequencer, Applied Biosystems) and the phenylthiohydantoin derivatives were identified and measured using reverse-phase high performance liquid chromatography (SP8100, Spectra-Physics) with an acetonitrile gradient system. 10)
Primary structure. Total RNA was extracted from IMR-90 cells stimulated by proteose peptone by the published method11* and the poly(A) RNA was selected by oligo(dT)-cellulose chromatography. 12) Double stranded CDNA was synthesized by the Okayama-Berg procedure13) and an E. coli strain, DH5, was transformed with the chimeric plasmid. Therefore, the purified PA preparation was free from urokinase type PA. SDS-PAGE of the purified PA showed a single band (Fig. 1) . The molecular weight was 64,000 to 68,000 by SDS-PAGE, very similar to that of tissue plasminogen activator (t-PA) from human melanoma cells,5) and about 69,000 to 72,000 by gel filtration on Sephacryl S-200. N-terminal amino acid sequence. To identify the purified PA, the N-terminus was sequenced (Fig. 2) . The PA produced and purified in the presence of 50 KlU/ml of aprotinin showed two amino acid sequences, one starting with glycine and the other with serine. N-Terminal sequences of the PA purified in the presence of 50 KlU/ml of aprotinin coincided with those of the melanoma t-PA purified in the presence of 25 KlU/ml of aprotinin.17) Therefore, the Plasminogen Activator from IMR-90 Cells.
The plasminogen activator was produced and purified under the presence of 4 or 50KlU/ml of aprotinin. Final concentration of each metal salt was 1 mM.
and t-PA from melanoma cells were identical. Although the nucleotide changes at two sites in the coding region and some differences in the 3' non-coding region were found between the cDNAsas shown in Fig. 3 Fibroblast t-PA and urokinase had optimum pHs of around 9 (Fig. 4) . Fibroblast t-PA was stable in the pH range of 5 to 10, which range was narrower than that of urokinase (Fig. 5) . The optimum temperatures of fibroblast t-PA and urokinase were 41°C (Fig. 6 ). Fibroblast t-PA was not inactivated by heating at 95°C for five min but urokinase was labile to heat (Fig. 7) .
Effects ofinhibitors.
The activity offibroblast t-PA was inhibited by leupeptin, /?-aminobenzamidine, gabexate mesilate and diisopro- Final concentration of each inhibitor was 250 /ig/ml. pyl fluorophosphate (DFP). On the other hand, the activity of urokinase was further inhibited by benzamidine and ra-aminobenzamine than by the above inhibitors (Table IV) .
Binding to fibrin. Approximately 83% of total t-PA activity was bound to fibrin (Table  V) . Apparently fibroblast t-PA had a higher affinity for fibrin than urokinase.
Immunological characterization.
The fibrinolytic activity of fibroblast t-PA was quenched completely by anti-t-PA IgG but those of high and low molecular weight urokinases were not. On the contrary, the activity of fibroblast t-PA was not quenched by anti-urokinase IgG, but those of high and low molecular weight urokinases were completely quenched. From the results, it was found that fibroblast t-PA was immunologically unrelated to urokinase.
